MedPage Today

Neuromyelitis Optica Spectrum Disorder: A Focus on Executive Dysfunction

In patients with NMOSD, there is a decline in executive function in terms of sustained attention, phonological verbal fluency, and working memory. Neuropsychological assessments in the clinical ...
MedPage Today

Neuromyelitis Optica Spectrum Disorder and Vitamin D: Is There a Link?

"Multi-center randomized controlled trials with large samples will further confirm the association between vitamin D and NMOSD. It may be necessary for doctors to assess the vitamin D levels of ...
Medscape

Neuromyelitis Optica Spectrum Disorder

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
MM&M

Alexion Pharmaceuticals spotlights rare disease NMOSD in short film

Alexion Pharmaceuticals, AstraZeneca’s rare disease unit, shined a light on neuromyelitis optica spectrum disorder (NMOSD), a severe neurological disease, in a short film that debuted Thursday. While ...
Healio

FDA approves Ultomiris for neuromyelitis optica spectrum disorder

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...
Business Wire

CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products ...
WebMD

Your Guide to Enspryng for Neuromyelitis Optica Spectrum Disorder

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that mostly affects your eyes and spinal cord. Your immune system attacks a specific protein, called aquaporin-4 (AQP4). The ...
Nasdaq

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

WILMINGTON, Del.--(BUSINESS WIRE)-- ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult ...
Business Wire

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Enspryng is the first approved medicine for NMOSD in Taiwan Subcutaneous injection for the treatment of NMOSD in both adults and adolescents Enspryng is the first approved medicine applying Chugai’s ...